Synmosa Biopharma Overview
Synmosa Biopharma (4114.TWO) has a ROE of 8.97%, below the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow8.97%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 4114.TWO is 8.97%. That is below the sector sector average of 11.64%. Investors often review this figure alongside Synmosa Biopharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 4114.TWO currently prints 8.97% for ROE, while the sector average sits near 11.64%. That is roughly 22.9% below the sector mean. Large gaps often invite a closer look at Synmosa Biopharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Synmosa Biopharma converts resources into returns. At 8.97%, 4114.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4114.TWO's ROE (8.97%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
